421 research outputs found

    Concert: Campus Chorus Ensemble

    Get PDF

    Proton Interaction Vertex Imaging With Silicon-Pixel CMOS Telescope For Carbon Therapy Quality control

    Get PDF
    International audienceMonitoring of the dose deposition during carbon ion therapy is a crucial issue for the quality control of such treatments. Recent studies have demonstrated that an ion-range control with millimeter resolution is feasible on a pencil-beam basis in homogeneous targets with prompt gamma detection for proton beams [1] and with Proton Interaction Vertex Imaging (PIVI) for carbon beams [2]. The present communication aims at describing our experimental and Monte Carlo simulation results. [1] J. Smeets et al., Phys. Med. Biol. 57 (2012) 3371-3405 [2] P. Henriquet et al., Phys. Med. Biol. 57 (2012) 4655-466

    Chlorpromazine versus placebo for schizophrenia

    Get PDF

    Real-Time Online Monitoring of the Ion Range by Means of Prompt Secondary Radiations

    Get PDF
    International audiencePrompt secondary radiations such as gamma rays and protons can be used for ion-range monitoring during ion therapy either on an energy-slice basis or on a pencil-beam basis. We present a review of the ongoing activities in terms of detector developments, imaging, experimental and theoretical physics issues concerning the correlation between the physical dose and hadronic processe

    Uncovering the stellar structure of the dusty star-forming galaxy GN20 at z=4.055 with MIRI/JWST

    Get PDF
    Luminous infrared galaxies at high redshifts (zz>4) include extreme starbursts that build their stellar mass over short periods of time (>100 Myr). These galaxies are considered to be the progenitors of massive quiescent galaxies at intermediate redshifts (z∌z\sim2) but their stellar structure and buildup is unknown. Here, we present the first spatially resolved near-infrared imaging of GN20, one of the most luminous dusty star-forming galaxies known to date, observed at an epoch when the Universe was only 1.5 Gyr old. The 5.6ÎŒ\mum image taken with the JWST Mid-Infrared Instrument (MIRI/JWST) shows that GN20 is a very luminous galaxy (M1.1ÎŒm,AB_\mathrm{1.1\mu m,AB}=−-25.01), with a stellar structure composed of a conspicuous central source and an extended envelope. The central source is an unresolved nucleus that carries 9% of the total flux. The nucleus is co-aligned with the peak of the cold dust emission, and offset by 3.9 kpc from the ultraviolet stellar emission. The diffuse stellar envelope is similar in size to the clumpy CO molecular gas distribution. The centroid of the stellar envelope is offset by 1 kpc from the unresolved nucleus, suggesting GN20 is involved in an interaction or merger event supported by its location as the brightest galaxy in a proto-cluster. The stellar size of GN20 is larger by a factor of about 3-5 than known spheroids, disks, and irregulars at z∌z\sim4, while its size and low S\'ersic index are similar to those measured in dusty, infrared luminous galaxies at z∌z\sim2 of the same mass. GN20 has all the ingredients necessary for evolving into a massive spheroidal quiescent galaxy at intermediate zz: it is a large, luminous galaxy at zz=4.05 involved in a short and massive starburst centred in the stellar nucleus and extended over the entire galaxy, out to radii of 4 kpc, and likely induced by the interaction or merger with a member of the proto-cluster.Comment: 7 pages, 4 figure

    Life beyond 30: Probing the −20 < M UV < −17 Luminosity Function at 8 < z < 13 with the NIRCam Parallel Field of the MIRI Deep Survey

    Get PDF
    We present the ultraviolet luminosity function and an estimate of the cosmic star formation rate density at 8 8 galaxy candidates based on their dropout nature in the F115W and/or F150W filters, a high probability for their photometric redshifts, estimated with three different codes, being at z > 8, good fits based on χ2 calculations, and predominant solutions compared to z < 8 alternatives. We find mild evolution in the luminosity function from z ∌ 13 to z ∌ 8, i.e., only a small increase in the average number density of ∌0.2 dex, while the faint-end slope and absolute magnitude of the knee remain approximately constant, with values α = − 2.2 ± 0.1, and M* = − 20.8 ± 0.2 mag. Comparing our results with the predictions of state-of-the-art galaxy evolution models, we find two main results: (1) a slower increase with time in the cosmic star formation rate density compared to a steeper rise predicted by models; (2) nearly a factor of 10 higher star formation activity concentrated in scales around 2 kpc in galaxies with stellar masses ∌108M⊙ during the first 350 Myr of the universe, z ∌ 12, with models matching better the luminosity density observational estimations ∌150 Myr later, by z ∌ 9

    Life beyond 30: Probing the-20 < M (UV) <-17 Luminosity Function at 8 < z < 13 with the NIRCam Parallel Field of the MIRI Deep Survey

    Get PDF
    We present the ultraviolet luminosity function and an estimate of the cosmic star formation rate density at 8 8 galaxy candidates based on their dropout nature in the F115W and/or F150W filters, a high probability for their photometric redshifts, estimated with three different codes, being at z > 8, good fits based on χ 2 calculations, and predominant solutions compared to z < 8 alternatives. We find mild evolution in the luminosity function from z ∌ 13 to z ∌ 8, i.e., only a small increase in the average number density of ∌0.2 dex, while the faint-end slope and absolute magnitude of the knee remain approximately constant, with values α = − 2.2 ± 0.1, and M * = − 20.8 ± 0.2 mag. Comparing our results with the predictions of state-of-the-art galaxy evolution models, we find two main results: (1) a slower increase with time in the cosmic star formation rate density compared to a steeper rise predicted by models; (2) nearly a factor of 10 higher star formation activity concentrated in scales around 2 kpc in galaxies with stellar masses ∌108 M ⊙ during the first 350 Myr of the universe, z ∌ 12, with models matching better the luminosity density observational estimations ∌150 Myr later, by z ∌ 9

    Strong (Hb + [OIII]) and Ha emitters at redshift z ~ 7-8 unveiled with JWST/NIRCam and MIRI imaging in the Hubble eXtreme Deep Field (XDF)

    Get PDF
    The JWST is revolutionizing the study of high-redshift galaxies by providing for the first time a high-sensitivity view of the early Universe at infrared wavelengths, both with its Near Infrared Camera (NIRCam) and Mid Infrared Instrument (MIRI). In this paper, we make use of medium and broad-band NIRCam imaging, as well as ultra-deep MIRI 5.6 microns imaging, in the Hubble eXtreme Deep Field (XDF) to identify prominent line emitters at z ~ 7-8. Out of a total of 58 galaxies at z ~ 7-8, we find 18 robust candidates (~31%) for prominent (Hb + [OIII]) emitters, based on their enhanced fluxes in the F430M and F444W filters, with rest-frame EW(Hb + [OIII]) ~ 87 - 2100 A. Among these emitters, 16 lie on the MIRI coverage area and 12 show a clear flux excess at 5.6 microns, indicating the simultaneous presence of a prominent Ha emission line with rest-frame EW(Ha) ~ 200 - 3000 A. This is the first time that Ha emission can be detected in individual galaxies at z>7. The Ha line, when present, allows us to separate the contributions of the Hb and [OIII] emission lines to the (Hb + [OIII]) complex and derive Ha-based star formation rates (SFRs). We find that in some cases [OIII]/Hb > 1, suggesting low metallicities, but a few have [OIII]/Hb < 1, so the NIRCam flux excess is mainly driven by Hb. The vast majority of prominent line emitters are very young starbursts or galaxies on their way to/from the starburst cloud. They make for a cosmic SFR density log10(SFRD_Ha / Msun yr^-1 Mpc^-3) ~ 2.35, which is about a third of the total value at z ~ 7-8. Therefore, the strong Ha emitters likely had an important role in reionization.Comment: 15 pages, 9 figures. Submitted to Ap

    Ovarian damage from chemotherapy and current approaches to its protection

    Get PDF
    BACKGROUND: Anti-cancer therapy is often a cause of premature ovarian insufficiency and infertility since the ovarian follicle reserve is extremely sensitive to the effects of chemotherapy and radiotherapy. While oocyte, embryo and ovarian cortex cryopreservation can help some women with cancer-induced infertility achieve pregnancy, the development of effective methods to protect ovarian function during chemotherapy would be a significant advantage.OBJECTIVE AND RATIONALE: This paper critically discusses the different damaging effects of the most common chemotherapeutic compounds on the ovary, in particular, the ovarian follicles and the molecular pathways that lead to that damage. The mechanisms through which fertility-protective agents might prevent chemotherapy drug-induced follicle loss are then reviewed.SEARCH METHODS: Articles published in English were searched on PubMed up to March 2019 using the following terms: ovary, fertility preservation, chemotherapy, follicle death, adjuvant therapy, cyclophosphamide, cisplatin, doxorubicin. Inclusion and exclusion criteria were applied to the analysis of the protective agents.OUTCOMES: Recent studies reveal how chemotherapeutic drugs can affect the different cellular components of the ovary, causing rapid depletion of the ovarian follicular reserve. The three most commonly used drugs, cyclophosphamide, cisplatin and doxorubicin, cause premature ovarian insufficiency by inducing death and/or accelerated activation of primordial follicles and increased atresia of growing follicles. They also cause an increase in damage to blood vessels and the stromal compartment and increment inflammation. In the past 20 years, many compounds have been investigated as potential protective agents to counteract these adverse effects. The interactions of recently described fertility-protective agents with these damage pathways are discussed.WIDER IMPLICATIONS: Understanding the mechanisms underlying the action of chemotherapy compounds on the various components of the ovary is essential for the development of efficient and targeted pharmacological therapies that could protect and prolong female fertility. While there are increasing preclinical investigations of potential fertility preserving adjuvants, there remains a lack of approaches that are being developed and tested clinically
    • 

    corecore